ERCC1在局部区域晚期鼻咽癌中的表达及临床意义  

ERCC1 expression in local regionally advanced nasopharyngeal carcinoma and its clinical significance

作　　者：曹轶林[1] 邱小芬[1] 邓恋[1] 屈元姣[1] 

机构地区：[1]广西壮族自治区南溪山医院肿瘤科,桂林541002

出　　处：《中国癌症防治杂志》2016年第4期221-224,共4页CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT

摘　　要：目的探讨核苷酸切除修复交叉互补基因1(excision repair cross complementing 1,ERCC1)在局部区域晚期鼻咽癌(nasopharyngeal carcinoma,NPC)组织中的表达及其临床意义。方法收集2013年1月至2015年6月收治的以接受顺铂为基础化疗的102例局部区域晚期NPC癌组织标本作为观察组,同时选取其中31例局部区域晚期NPC癌旁上皮组织为对照组。采用免疫组化法检测两组组织中ERCC1的表达,并分析ERCC1表达与局部区域晚期NPC患者临床病理参数及化疗疗效的关系。结果观察组和对照组ERCC1的阳性表达率分别为62.7%和90.3%,差异有统计学意义(P<0.05)。ERCC1表达与局部区域晚期NPC患者年龄有关(P<0.05),与性别、T分期、N分期无关(P>0.05)。ERCC1表达阳性的患者化疗有效率为35.9%,ERCC1表达阴性患者为63.2%,差异有统计学意义(P=0.019)。结论 ERCC1在局部区域晚期鼻咽癌癌组织中低表达,ERCC1表达与化疗疗效呈负相关,检测ERCC1有助于预测局部区域晚期NPC患者对顺铂化疗的敏感性。Objective To determine the status of ERCC1 protein expression and its potential clinical significance in patients with local regionally advanced nasopharyngeal carcinoma （NPC）. Methods Nasopharyngeal endoscopy biopsies were collected from 102 patients with local regionally advanced NPC at diagnosis, and biopsies of cancer-adjacent normal nasopharyngeal tissues were collected from 31 patients. ERCC1 expression in the two sets of samples was compared by immunohistochemistry using monoclonal antibody. Results Rate of ERCC1 expression was 90.3% in NPC tissues and 62.7% in adjacent tissues （P〈0.05）. Rate of response to cisplatinbased chemotherapy was 35.9% in patients positive for ERCC1 expression and 63.2% in patients negative for ERCC1 （P〈0.05）. ERCC1 expression correlated significantly with age,but not with gender or TN stage. Conclusion ERCC1 is expressed at low levels in local regionally advanced NPC, and its expression correlates negatively with chemosensitivity. ERCC1 may be useful for predicting sensitivity of NPC patients to cisplatin-based chemotherapy.

关 键 词：鼻咽肿瘤 局部区域晚期鼻咽癌 核苷酸切除修复交叉互补基因1 顺铂 化疗 疗效 敏感性 

分 类 号：R739.6[医药卫生—肿瘤]